Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Operating Leases (2020 - 2025)

Bolt Biotherapeutics' Operating Leases history spans 6 years, with the latest figure at $20.9 million for Q3 2025.

  • For Q3 2025, Operating Leases rose 36.06% year-over-year to $20.9 million; the TTM value through Sep 2025 reached $20.9 million, up 36.06%, while the annual FY2024 figure was $23.0 million, 31.66% up from the prior year.
  • Operating Leases for Q3 2025 was $20.9 million at Bolt Biotherapeutics, down from $21.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $23.2 million in Q2 2021 and bottomed at $9.1 million in Q1 2021.
  • The 5-year median for Operating Leases is $20.7 million (2022), against an average of $19.4 million.
  • The largest annual shift saw Operating Leases soared 135.34% in 2022 before it decreased 15.85% in 2024.
  • A 5-year view of Operating Leases shows it stood at $21.9 million in 2021, then fell by 7.48% to $20.2 million in 2022, then fell by 13.76% to $17.4 million in 2023, then skyrocketed by 31.66% to $23.0 million in 2024, then fell by 9.01% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Operating Leases are $20.9 million (Q3 2025), $21.6 million (Q2 2025), and $22.3 million (Q1 2025).